[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Benedetti-Panici P, Zullo MA, Plotti F, Manci N, Muzii L, Angioli R: Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy. Cancer; 2004 May 15;100(10):2110-7
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy.
  • BACKGROUND: The objective of the current study was to evaluate the incidence of long-term bladder dysfunction after type 3-4 radical hysterectomy in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy (NACT).
  • METHODS: A case-control study was conducted to evaluate the occurrence of long-term bladder dysfunction in 76 patients with International Federation of Gynecology and Obstetrics Stage IB-IIA (> 4 cm), Stage IIB, and Stage III cervical carcinoma who underwent type 3-4 radical hysterectomy after NACT.
  • Three main disturbances were found: detrusor overactivity (21%), mixed urinary incontinence (24%), and de novo stress incontinence (21%).
  • Among patients who underwent type 4 radical hysterectomy, the extent of caudal resection of rectovaginal ligaments and vaginal tissue was found to be more strongly associated with bladder dysfunction than was the extent of lateral parametrial resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hysterectomy. Urinary Bladder / physiopathology. Uterine Cervical Neoplasms / physiopathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Time Factors. Urinary Incontinence, Stress / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139052.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Stewart AJ, Viswanathan AN: Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer. Cancer; 2006 Sep 1;107(5):908-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer.
  • The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago.
  • However, certain aspects of the use of high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy.
  • This study represents a systematic literature review of prospective and retrospective series of patients with cervical carcinoma treated with external-beam radiation (EBRT) followed by either HDR or LDR radiation.
  • The local control rates, survival rates, and treatment-related complications in patients with Stage III cervical cancer treated with HDR or LDR and those treated with concomitant chemotherapy are examined.
  • Patients with Stage III cervical cancer treated with EBRT and brachytherapy have a local control rate of >50% in most series.
  • However, LDR may be preferable for large, bulky tumors at the time of brachytherapy.
  • Retrospective studies of HDR and concurrent chemotherapy are limited but have demonstrated toxicity rates similar to those with LDR.
  • Selected patients with Stage III cervical carcinoma who have an adequate response to EBRT and concomitant chemotherapy may be treated with HDR brachytherapy.
  • The existing literature shows no significant increase in complications in patients treated with HDR and concurrent chemotherapy; however, sufficient tumor shrinkage prior to HDR and careful monitoring of the dose to the normal tissues are imperative.
  • [MeSH-major] Brachytherapy / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Dose Fractionation. Female. Humans. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874815.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


3. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ: Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer; 2003 Feb 1;97(3):568-74
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis.
  • BACKGROUND: The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine (NE) cervical carcinoma.
  • METHODS: All patients with NE cervical carcinoma diagnosed between 1979-2001 were identified from tumor registry databases at two hospitals.
  • The impact of clinical and pathologic risk factors on the survival of patients with small cell NE carcinoma of the cervix was evaluated using Kaplan-Meier life table analyses and log-rank tests.
  • RESULTS: Thirty-four patients (median age, 42 years) were diagnosed with neuroendocrine cervical carcinoma, which included 21 with International Federation of Gynecology and Obstetrics (FIGO) Stage I disease, 6 with FIGO Stage II disease, 5 with FIGO Stage III disease, and 2 with FIGO Stage IV disease.
  • Fourteen women received adjuvant therapy with pelvic radiation and/or cisplatin-based chemotherapy.
  • Ten women received primary radiotherapy with (n = 5) or without (n = 4) chemotherapy and the remaining patient refused therapy.
  • Women with early-stage (Stage I-IIA) disease had median survival rates of 31 months compared with 10 months in the advanced-stage (Stage IIB-IVB) group (P = 0.002).
  • In univariate analysis, advanced stage (P = 0.002), tumor size >2 cm (P = 0.02), margin involvement (P = 0.016), pure versus a mixed histologic pattern (P = 0.04), margin status (P = 0.016), and smoking (P = 0.04) were considered poor prognostic factors.
  • In multivariate analysis, smoking for early-stage patients and stage of disease in the overall population remained as independent prognostic factors of survival.
  • CONCLUSIONS: Smoking and advanced stage are reported to be poor prognostic factors for survival in patients with NE small cell carcinoma of the cervix.
  • The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions.
  • [MeSH-major] Carcinoma, Small Cell / mortality. Uterine Cervical Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11086
  • (PMID = 12548598.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Monk BJ, Tian C, Rose PG, Lanciano R: Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol Oncol; 2007 May;105(2):427-33
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.
  • PURPOSE: To explore clinical/pathologic factors associated with prognosis of patients with locally advanced cervical carcinoma treated with weekly cisplatin and pelvic radiation.
  • RESULTS: Four-year PFS and OS for stage II patients were 64.2% and 68.1%, respectively for those treated on GOG 120 and 65.8% and 73.9% for those treated on GOG 165, compared to 51.4% and 55.4% for stage III/IV patients respectively treated on GOG 120 and 37.7% and 42.7% respectively for those treated on GOG 165.
  • In multivariate analysis, stage, tumor grade, race and age were independently predictive of PFS and OS (for all, p<0.05).
  • CONCLUSIONS: FIGO stage, tumor grade, race and age are prognostic in patients with locally advanced cervical carcinoma treated with concurrent cisplatin and radiation.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 2000 Dec;60(6):1239-44 [11152009.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):218s-223s [12743138.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):741-50 [15361180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):667-76 [2004942.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2776-85 [2025841.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):31-46 [8115784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1301-7 [7635769.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1527-9 [7635797.001]
  • [Cites] Radiother Oncol. 1995 May;35(2):107-17 [7569018.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1141-9; discussion 1149-50 [8623841.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(21):1-148 [9101701.001]
  • [Cites] JAMA. 1997 Oct 1;278(13):1096-101 [9315770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):351-8 [10030261.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1144-53 [15519786.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):721-8 [15721417.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):183-91 [15790456.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):667-71 [15927409.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8289-95 [16230678.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):869-73 [11241257.001]
  • [Cites] Semin Radiat Oncol. 2000 Jan;10(1):36-43 [10671657.001]
  • (PMID = 17275889.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA087558-04; United States / NCI NIH HHS / CA / K23 CA87558; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA087558-04; United States / NCI NIH HHS / CA / K23 CA087558
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS22745; NLM/ PMC1940233
  •  go-up   go-down


5. Zhang MQ, Liu SP, Wang XE: Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):821-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
  • PURPOSE: To evaluate the efficacy and toxicities of concurrent chemoradiotherapy (CCRT) and consolidation chemotherapy in patients with locally advanced squamous cell cervical carcinoma.
  • METHODS AND MATERIALS: Patients with LASCC (FIGO Stage IIB-IIIB) were treated with pelvic external beam radiotherapy (45 Gy for Stage IIB and 50 Gy for Stage III) and high-dose-rate intracavitary brachytherapy (50 Gy for Stage IIB and 35 Gy for Stage III).
  • The cumulative dose at point A was 50 Gy for Stage IIB and 65 Gy for Stage III.
  • Concurrent chemotherapy with paclitaxel (35 mg/m(2)) and nedaplatin (20 mg/m(2)) was given every week for 6 weeks.
  • Consolidation chemotherapy with paclitaxel (135 mg/m(2)) and nedaplatin (60 mg/m(2)) was administered every 3 weeks for 4 cycles.
  • RESULTS: All patients completed CCRT, and 28 of 34 patients completed consolidation chemotherapy.
  • CONCLUSIONS: CCRT with paclitaxel and nedaplatin followed by consolidation chemotherapy is well tolerated and effective in patients with locally advanced squamous cell cervical carcinoma.
  • Further randomized trials of comparing this regimen with the standard treatment are worth while.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Leukopenia / etiology. Middle Aged. Neoplasm Staging. Neutropenia / etiology. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiotherapy / methods. Remission Induction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20207507.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Mossa B, Mossa S, Corosu L, Marziani R: Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma. Eur J Gynaecol Oncol; 2010;31(5):497-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma.
  • OBJECTIVE: To assess the role of neoadjuvant chemotherapy to achieve radical surgery in a larger number of patients with locally advanced/or bulky Stage IB cervical carcinoma.
  • We conducted a trial to determine whether neoadjuvant chemotherapy would improve disease-free survival and overall survival in Stage IB-III cervical cancer.
  • METHODS: 288 patients with squamous cell carcinoma of the uterine cervix, FIGO Stage IB-IIIB were randomized to one of the following treatments: three courses of neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 159); conventional surgery or exclusive radiotherapy (CONV arm; n = 129).
  • There was no difference in age, FIGO stage, tumor size and lymph node involvement between the two groups (p = ns).
  • Two hundred and thirty-four patients in Stage IB-IIb (n = 129 NACT arm and n = 105 CONV arm) and 24 patients in Stage III (NACT arm) who proved to be chemosensitive underwent radical hysterectomy.
  • Six Stage III patients, non responders to chemotherapy, and 24 patients, Stage III of the CONV arm, underwent radiotherapy.
  • RESULTS: The study was performed on disease-free survival related to several prognostic factors: age, FIGO stage, tumor size, grading, parametrial involvement, lymph node status and surgical margins.
  • Statistically significant differences in the recurrence of the disease were related to FIGO stage (p < 003), grading (p < .05), parametrial involvement (p < .002) lymph node status (p < .0001) and tumor size (p <.002).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Hysterectomy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoadjuvant Therapy. Radiotherapy. Vincristine / administration & dosage


7. Nobeyama H, Sumi T, Misugi F, Okamoto E, Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K, Ishiko O: Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. Int J Mol Med; 2004 Jul;14(1):101-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer.
  • Whether the human papillomavirus (HPV) status of the tumor affects the sensitivity to neoadjuvant chemotherapy, and the prognosis in advanced uterine cervical cancer (FIGO stage III or higher) remains unknown.
  • We examined the HPV status of 43 patients who had received CDDP therapy by balloon-occluded arterial infusion (BOAI), as neoadjuvant chemotherapy for advanced uterine cervical cancer (squamous cell carcinoma) stage III or higher.
  • DNA was extracted from formalin-fixed, paraffin-embedded tumor samples obtained by punch biopsy before the neoadjuvant chemotherapy.
  • The detection of HPV and its typing were analyzed by a polymerase chain reaction (PCR)-based assay using consensus primers for the L1 consensus regions.
  • The HPV types were divided into 3 groups, HPV 16, HPV 33 and other HPV types (HPV 18, 31, 35, 58), and comparisons and examinations were performed among the 3 groups.
  • Although the rates of tumor reduction and operation accomplishment after 3 courses of BOAI showed no significant differences among the 3 groups, there were significant differences in the survival rates.
  • The survival rate of advanced uterine cervical cancer patients with HPV 33 infection was the highest, followed by that of patients with HPV 16 infection.
  • The survival rates of patients with the other types of HPV infection were the worst among the 3 groups and significantly lower than those of patients with HPV 16 or HPV 33 infection.
  • The differences in the curative effect after BOAI may depend on the different characters of the HPV types.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. DNA, Viral / analysis. Female. Humans. Middle Aged. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Prognosis


8. Jain VS, Singh KK, Shrivastava R, Saumsundaram KV, Sarje MB, Jain SM: Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India. J Cancer Res Ther; 2007 Oct-Dec;3(4):211-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India.
  • AIM: To report the outcome of carcinoma of the uterine cervix patients treated radically by external beam radiotherapy (EBRT) and high-dose-rate (HDR) intracavitary radiotherapy (ICRT).
  • MATERIALS AND METHODS: Between January 1997 to December 2001, a total of 550 newly diagnosed cases of carcinoma of the uterine cervix were reported in the department.
  • All cases were staged according to the International Federation of Gynecologists and Oncologists (FIGO) staging system, but for analytical convenience, the staging was limited to stages I, II, III, and IV.
  • RESULTS: There were 7 (3.27%), 88 (41.1%), 101 (47.1%), and 18 (8.4%) patients in stage I, II, III, and IV, respectively.
  • The median follow-up time for all patients was 43 months (range: 3-93 months) and for patients who were disease free till the last follow-up it was 59 months (range: 24-93 months).
  • The overall treatment time (OTT) ranged from 52 to 73 days (median 61 days).
  • The 5-year disease-free mean survival rate was 58%, 44%, 33%, and 15%, with 95% confidence interval of 48 to 68, 37 to 51, 24 to 35, and 6 to 24 for stages I, II, III, and IV, respectively.
  • There were 62 (28.97%) cases with local residual disease, 35 (16.3%) developed local recurrence/distant metastases, 17 (7.9%) developed distant metastases, and 9 (4.2%) had local recurrence as well.
  • DISCUSSION AND CONCLUSION: The overall outcome was poor in advanced stage disease, but might be improved by increasing the total dose, decreasing overall duration of treatment, and by adding chemotherapy in patients with disease limited to the pelvis.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. India. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Prognosis. Retrospective Studies. Rural Population. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270396.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Kornovski Y, Gorchev G: Histopathological findings in postoperative specimens in cervical cancer patients with stages IB2-IVA after neoadjuvant chemotherapy and preoperative plus postoperative radiotherapy. J BUON; 2007 Jan-Mar;12(1):57-63
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological findings in postoperative specimens in cervical cancer patients with stages IB2-IVA after neoadjuvant chemotherapy and preoperative plus postoperative radiotherapy.
  • PURPOSE: To determine the incidence of the histopathological findings indicative for risk of recurrence in patients with locally advanced cervical cancer (LACC) who were treated with neoadjuvant chemotherapy (NCT) and radiation therapy (RT) before operation.
  • PATIENTS AND METHODS: Sixty-three patients were included: 45 patients (group 1) underwent external beam RT and then surgical treatment followed by postoperative RT, and 18 (group 2) patients were treated with NCT and surgery followed by postoperative RT.
  • Surgery was class III-V radical hysterectomy with pelvic lymph node dissection (LND), and paraaortic LND at indication.
  • In group 1 FIGO stage IIB prevailed (n=29, 64.4%).
  • Forty-four (97.8%) patients had squamous cell carcinoma and 1 (5.6%) adenosquamous carcinoma.
  • In group 2 stage IIB also prevailed (n=13, 72.2%), whereas all 18 (100%) patients had squamous cell carcinoma.
  • RESULTS: In group 1 lymph node metastases (LNM) were found in 35.56% of the cases, macroscopically detectable LNM in 15.6%, LNM above the common iliac artery level in 11.1%, multiple LNM (>3 LNM) in 17.8%, parametrial invasion in 4.4%, deep stromal invasion in 31.1%, lymphovascular space invasion (LVSI) in 13.3%, infiltration of canalis cervicalis in 15.6%, infiltration of isthmus uteri in 8.9% and ovarian metastases in 4.4%.
  • CONCLUSION: NCT followed by surgical treatment and RT leads to postoperative histological results that are not worse than the standard preoperative RT approach.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Bulgaria / epidemiology. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Incidence. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Prospective Studies. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436403.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  •  go-up   go-down


10. Kornovski Y, Gorchev G: Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA. J BUON; 2006 Jul-Sep;11(3):291-7
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA.
  • PURPOSE: To compare the 2-year recurrence-free survival, recurrence rates and their localization after treatment with definitive radiation therapy (RT) vs. neoadjuvant chemotherapy (NCT) followed by radical surgery and post-operative RT in cervical cancer patients with FIGO stages IIB through IVA.
  • PATIENTS AND METHODS: 43 patients were included in the study, 25 of whom (group 1) were treated with pelvic RT(50-52 Gy external beam RT) and 18 (group 2) with NCT followed by surgery and postoperative RT(50-52 Gy).
  • The operations performed were class III-V radical hysterectomy with total pelvic and paraaortic lymph node dissection.
  • In group 1, 17 (68%) patients were staged IIB and 8 (32%) IIIB; 23 (92%) patients had squamous cell carcinoma and 2 (8%) adenocarcinoma.
  • All 18 patients had squamous cell carcinoma.
  • CONCLUSION: In FIGO stages IIB-IVA cervical cancer patients cisplatin-based NCT followed by surgery and postoperative external beam RT lead to a better 2-year recurrence-free survival compared to pelvic RT alone.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hysterectomy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local. Pelvis / radiation effects. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309152.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Berclaz G, Gerber E, Beer K, Aebi S, Greiner R, Dreher E, Buser K: Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy. Int J Oncol; 2002 Jun;20(6):1313-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy.
  • Recently randomized trials show an overall survival advantage of 30% for cisplatin-based chemotherapy given concurrently with radiation therapy.
  • Current data do not allow to conclude which drugs could be best combined with cisplatin.
  • Here we report the very long-term results of a prospective phase II trial of concurrent radiochemotherapy in advanced cancer of the cervix.
  • Patient with squamous cell carcinoma of the cervix FIGO stage IIB, III or IVA received a concomitant chemotherapy with cisplatin, fluorouracil and mitomycin C and radiotherapy.
  • All 22 patients treated showed acute hematological toxicity and two patients developed severe late bowel toxicity.
  • Ten patients (45%) were alive after a median observation time of 145.5 months.
  • The lack of improvement compared to cisplatin alone and late bowel toxicity do not support the use of mitomycin C in the combination of the concurrent treatment of chemoradiation.
  • The psychological impact of this treatment should not be minimized.
  • Most problems tend to diminish with time with the exception of intestinal side effects and vaginal changes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Mitomycin / administration & dosage. Patient Compliance. Radiotherapy / adverse effects. Radiotherapy Dosage. Treatment Failure

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12012015.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Niibe Y, Tsunoda S, Jobo T, Imai M, Matsuo K, Matsunaga K, Unno N, Hayakawa K: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis. Eur J Gynaecol Oncol; 2008;29(3):222-4
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis.
  • OBJECTIVE: Locally advanced uterine cervical carcinoma (LAUCC) treated with chemoradiotherapy is considered to be the standard treatment regimen.
  • Furthermore, the total dose of Japanese radiation therapy protocol is less than that of the USA which indicated that chemoradiotherapy for LAUCC is better than radiation therapy alone by phase III clinical trials.
  • Nedaplatin is a platinum drug and no hydration is required to infuse patients because it is less toxic on renal function.
  • PATIENTS AND METHODS: Patients registered in the current study were found to have LAUCC based on the following criteria i) pathologically proven squamous cell carcinoma or adenocarcinoma, ii) FIGO clinical Stage Ib, IIa, IIb with bulky tumor (diameter > 40 mm assessed by pelvic magnetic resonance imaging) or pelvic lymph node swelling (diameter > 10 mm assessed by pelvic computed tomography);.
  • iii) FIGO clinical Stage IIIa, IIIb and IVa with no paraaortic lymph node swelling (diameter > 10 mm) observed by abdominal computed tomography;.
  • The treatment protocol was as follows: Radiation therapy in a combination of external beam radiation therapy (total dose: 50 Gy-52 Gy/25-27 fractions with central shielding after 30-32 Gy) with high-dose rate intracavitary irradiation (24-30 Gy/4-6 fractions to point A).
  • Chemotherapy applied in the current study was weekly nedaplatin infused intravenously (30 mg/mm2/time, once a week, total 150 mg/mm2/5 weeks).
  • As for clinical stage, nine were IIIb and only one was IIb.
  • Nine patients were proven to have squamous cell carcinoma and one adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell. Organoplatinum Compounds / therapeutic use. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592783.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


13. Mancebo G, Gil-Moreno A, Vergés R, Martínez-Palones JM, Checa MA, Carreras JM, Giralt J, Xercavins J: Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival. Eur J Gynaecol Oncol; 2010;31(1):18-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival.
  • PURPOSE OF INVESTIGATION: We assessed the feasibility, response rates, and overall survival of patients with locally advanced cervical cancer treated with cisplatin-based chemotherapy during radiation therapy on an out-of-protocol basis.
  • METHODS: Sixty-nine consecutive newly diagnosed untreated patients with locally advanced cervical cancer who received chemoradiation between 1999 and 2003 were retrospectively reviewed.
  • Treatment consisted in external beam radiation followed by one 137-cessium intracavitary application.
  • RESULTS: Treatment was well tolerated, although 52 patients presented some degree of acute adverse toxicity (gastrointestinal 65%, hematological 48%, genitourinary 10%).
  • The 3-year survival rate was 61.8% (95% CI 54.5-69.0), with a mean 41.8 months (95% CI 35.7-48.3).
  • Overall survival after adjusting by FIGO Stage IB2-IIA and IIB-IVA was 73.9% and 50%, respectively (p = 0.1839).
  • Overall survival according to Stages IB2-IIb and III-IVA was 74.8% and 34.9%, respectively (P = 0.0376).
  • CONCLUSION: In patients with locally advanced cervical cancer, adding a weekly regimen of cisplatin to standard pelvic radiation in an out-of-protocol basis is feasible, effective, and showed no unexpected toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Brachytherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Prognosis. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349775.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL: Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol; 2005 Jan;96(1):168-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
  • OBJECTIVES: Standard primary treatment for locally advanced cervix cancer is radiation (RT) with concomitant platinum-based chemotherapy (CT).
  • Paclitaxel and carboplatin are active agents in recurrent cervical carcinoma, have potent, synergistic in vitro radiosensitization, and are cytotoxic in weekly schedules.
  • This study was done to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly paclitaxel/carboplatin chemoradiotherapy in locally advanced cervix cancer.
  • METHODS: Women with primary, previously untreated, squamous cell or adenocarcinoma of the cervix, FIGO stage IB(2) to IVA, negative para-aortic lymph nodes, adequate organ function and performance status were eligible.
  • Pelvic RT (45 Gy over 5 weeks--180 cGy/day, four-field) was followed by two brachytherapy applications (Point A low dose rate (LDR): 90 Gy, high dose rate (HDR): 75 Gy).
  • A grade III-IV toxicity prompted up to three additional patients per dose level.
  • Median RT treatment time was 61 days (range, 55-79).
  • Fourteen patients received brachytherapy (LDR: 8, HDR: 6), and one received external RT only due to cervical stenosis.
  • One grade III ANC was observed at dose level II (AUC 2.0) but not seen in three additional patients.
  • At dose level IV (AUC 3.0), two grade III-IV ANC toxicities were observed in two patients (DLT).
  • One patient had grade III anemia.
  • Grade III/IV nonhematologic toxicity was rare (1/15 GI-nausea/vomiting, 1/15 pneumonia, 1/15 hypokalemia).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy / adverse effects. Brachytherapy / methods. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiotherapy / adverse effects. Radiotherapy / methods


15. Hagen B, Skjeldestad FE, Halvorsen T, Strickert T, Tingulstad S, Lorenz E, Onsrud M: Primary treatment of cervical carcinoma. Ten years experience from one Norwegian health region. Acta Obstet Gynecol Scand; 2000 Dec;79(12):1093-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary treatment of cervical carcinoma. Ten years experience from one Norwegian health region.
  • OBJECTIVE: To study the primary care of cervical carcinoma with regard to clinical and pathological factors, treatment decisions, complications and survival.
  • DESIGN: A historical cohort comprising all women hospitalized with invasive cervical carcinoma (n=293) during the period 1987-1996.
  • FIGO stage distribution was 62%, 15%, 18% and 5% in stages I, II, III and IV, respectively.
  • Early stage disease correlated with young age.
  • Histologic types were: squamous cell carcinoma 84%, adenocarcinoma 11%, adenosquamous carcinoma 4% and small cell/anaplastic carcinoma 1%.
  • Primary therapies were: surgery 188 women (64%), radiotherapy 99 women (34%), chemotherapy two women (0.7%); four women not treated (1.3%).
  • Five-year survival in stages IA, IB, II and III was 100%, 88%, 58% and 20%, respectively.
  • One-year survival in stage IV was 31%.
  • Median survival in stages III and IV according to curative or palliative aim of treatment was 20 and 6 months, respectively (p<0.005).
  • CONCLUSION: Satisfactory quality of diagnosis and therapy have been maintained through regional care for cervical cancer patients.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11130094.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


16. Kokawa K, Takekida S, Kamiura S, Kita M, Enomoto T, Kawaguchi R, Saito J, Horie A, Umesaki N: The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan. Eur J Gynaecol Oncol; 2010;31(1):37-43
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan.
  • OBJECTIVE: To determine the clinical characteristics of patients (young women) with cervical carcinoma aged less than 35 years.
  • METHODS: Data from patients who were treated for cervical carcinomas from 1990 to 2000 in the Kinki District were retrospectively investigated for clinical stage, histologic type, treatment procedure and prognosis.
  • The incidence of cervical carcinoma in these women was 7.9% from 1990 to 1995, 9.1% from 1996 to 2000, and 9.5% from 2001 to 2005.
  • FIGO Stage I included 374 cases, followed by, 49 in Stage II, 11 in Stage III, and seven in Stage IV.
  • Squamous cell carcinoma incidence was 80.7% and non-squamous cell carcinoma incidence was 19.3%.
  • Several types of surgery were performed in patients with Stage I and II, while patients with Stage III and IV were treated with radiotherapy and/or chemotherapy without any type of surgery.
  • The 5-year survival rate was 95% for Stage I disease, 73% for Stage II, 68% for Stage III, and 19% for Stage IV.
  • CONCLUSION: The incidence of cervical carcinoma in young women slightly increased from 1990 to 2005.
  • The prognosis of cervical carcinoma tends to be better in young women than in older patients, especially in Stage III disease.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Age Factors. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Female. Humans. Incidence. Japan / epidemiology. Lymphatic Metastasis. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349779.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Rath GK, Sharma DN, Julka PK, Subramani V, Bahl A, Haresh KP: Pulsed-dose-rate intracavitary brachytherapy for cervical carcinoma: the AIIMS experience. Am J Clin Oncol; 2010 Jun;33(3):238-41
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulsed-dose-rate intracavitary brachytherapy for cervical carcinoma: the AIIMS experience.
  • OBJECTIVE: The aim of present study was to analyze the results of pulsed-dose-rate (PDR) brachytherapy in patients with cervical carcinoma treated at our center.
  • METHODS: From September 2003 to September 2005, 48 patients with histopathologically proved cervical carcinoma, stages IB to IVA, were treated with PDR intracavitary radiotherapy (ICRT) and pelvic irradiation at our center.
  • Radiotherapy consisted of whole pelvis external beam radiation therapy (EBRT) with a dose of 40 Gy in 22 fractions over 4.5 weeks followed by 10 Gy in 5 fractions over 1 week with midline shielding.
  • Weekly chemotherapy (Cisplatin, 40 mg/m) was administered during the course of EBRT to suitable patients.
  • After an interval of 1 to 2 weeks, a single session of standard ICRT application was done to deliver a dose of 27 Gy to point A by PDR (hourly pulse, 70 cGy).
  • FIGO stage distribution of the patients was as follows: stage IB, 6; stage IIA, 1; stage IIB, 15; stage IIIB, 25; and stage IVA, 1.
  • Ten patients had disease recurrence (5 each in stage IIB and stage IIIB).
  • Overall grades III to IV late toxicity rate at 50 months was 6%.
  • For the median follow-up period of 15 months, the actuarial recurrence-free survival in stages I to II was 82% and stages III to IV was 78%.
  • CONCLUSION: Our results reveal that PDR ICRT in combination with pelvic EBRT provides excellent pelvic disease control, survival, and low radiation related morbidity rate in the patients with cervical carcinoma.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Cisplatin / therapeutic use. Cobalt Radioisotopes / therapeutic use. Combined Modality Therapy. Female. Humans. India. Kaplan-Meier Estimate. Middle Aged. Particle Accelerators. Radiotherapy Dosage. Radiotherapy, High-Energy. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841576.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cobalt Radioisotopes; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Brown Iii JV, Epstein HD, Kim R, Micha JP, Rettenmaier MA, Mattison JA, Goldstein BH: Rapid manifestation of CNS metastatic disease in a cervical carcinoma patient: a case report. Oncology; 2007;73(3-4):273-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid manifestation of CNS metastatic disease in a cervical carcinoma patient: a case report.
  • OBJECTIVES: Brain metastases originating from primary cervical carcinoma are very rare.
  • Despite surgery and adjuvant therapy, patient prognosis is extremely unfavorable.
  • Prior studies have reported that the median time from the primary disease's diagnosis to development of CNS metastases is approximately 18 months.
  • CASE REPORT: A 60-year-old woman was initially diagnosed and treated for FIGO clinical stage IB2 cervical carcinoma in March 2007.
  • The patient had surgery to resect the brain tumor and then received Gamma Knife stereotactic radiosurgery and chemotherapy.
  • CONCLUSION: The incidence of brain metastases originating from primary cervical carcinoma is very rare.
  • Since the presenting symptoms of CNS metastatic disease are not well characterized and patient prognosis is very poor, oncology physicians should anticipate the presence of this condition in order to provide prompt and comprehensive treatment.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Adenosquamous / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Ovariectomy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18424893.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Tan LT, Zahra M: Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. Clin Oncol (R Coll Radiol); 2008 Jun;20(5):358-64
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience.
  • AIM: To evaluate the long term cause-specific survival and late toxicity of chemoradiotherapy for carcinoma of the cervix treated outside research settings.
  • MATERIALS AND METHODS: Between May 1999 and April 2003, 74 patients with carcinoma of the cervix were treated with radical radiotherapy given concurrently with weekly cisplatin chemotherapy.
  • Three patients died during treatment, leaving 71 patients available for analysis of long-term survival and late toxicity of treatment.
  • In total, 56 patients (78.9%) received chemoradiotherapy as primary radical treatment.
  • Ten patients (14.1%) received chemoradiotherapy as adjuvant treatment after radical surgery.
  • The remaining five patients (7.0%) received chemoradiotherapy as salvage treatment for pelvic recurrences after previous surgery.
  • The actuarial 5-year cause-specific survival for the 66 patients undergoing primary treatment (chemoradiotherapy+/-surgery) was 54.6%.
  • The cause-specific survival by International Federation of Gynecology and Obstetrics (FIGO) disease stage was 58.3% for stage I disease, 69.9% for stage II disease and 20.8% for stage III disease.
  • The actuarial 5-year pelvic control rate for the same group of patients was 73.3% overall (stage I=79.2%, stage II=89.0%, stage III=33.3%).
  • Of the 66 patients undergoing primary treatment, seven (10.6%) had persistent disease after chemoradiotherapy.
  • Of the 22 patients (33.3%) who relapsed >6 months after treatment, eight (36.4%) relapsed within the pelvis alone, 12 (54.5%) had metastatic disease alone, whereas two (9.1%) had both local and distant relapse.
  • Eight of 23 patients (34.8%) with adenocarcinomas developed metastatic disease compared with only six of 43 patients (14.0%) with squamous cell tumours.
  • There were no significant correlations between the incidence of serious late toxicity and disease stage, field arrangement, treatment volumes or postoperative radiotherapy.
  • CONCLUSIONS: Our study has shown that the addition of chemotherapy to radiotherapy for cervical cancer probably improves the survival of patients treated outside research settings, but the benefit may not be as large as that obtained in clinical trials and the risk of serious late toxicity is increased.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Female. Humans. Middle Aged. Platinum Compounds / administration & dosage. Platinum Compounds / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395427.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


20. Niwa K, Kometani K, Sekiya T, Nakazawa K, Kanakura Y: Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin. Int J Clin Oncol; 2002 Jun;7(3):197-200
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin.
  • Endometrial cancer is believed to have a better prognosis than cervical cancer.
  • However, this is not necessarily true for cases beyond International Federation of Gynecology and Obstetrics (FIGO) stage III, and advanced endometrial cancer with distant metastases in particular has a poor prognosis.
  • Moreover, there is no established therapy for advanced endometrial cancer.
  • Recently, we treated two patients with endometrial cancer with multiple lung metastases (FIGO stage IVb).
  • In their postoperative course, the two patients successfully underwent T-J chemotherapy [paclitaxel: 210 m/m2 over 3h; carboplatin: area under the curve (AUC) 5].
  • Multiple lung shadows in chest X-P and computed tomography (CT) were reduced in number and size after two courses of T-J chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Anemia. Area Under Curve. Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Japan. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiography, Thoracic. Remission Induction. Time Factors. Tomography, X-Ray Computed. Uterine Hemorrhage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12109523.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, Buttarelli M, Moutardier V, Goncalves A, Resbeut M: Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol; 2006 Feb;100(2):338-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma.
  • OBJECTIVE: To report the long-term survival of 35 patients who underwent surgery after concomitant chemoradiation for locally advanced cervical cancers.
  • METHODS: From 1988 to 1992, 20 bulky IB-IIB patients and 15 stage III-IVA patients underwent surgery after concurrent chemotherapy (CDDP and 5-FU) and radiotherapy.
  • Analysis included FIGO stage, type of surgery (palliative or curative), response to chemoradiation or para-aortic lymphatic status.
  • Only the type of surgery significantly affected the OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Hysterectomy. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pelvic Exenteration. Treatment Outcome


22. Lorvidhaya V, Chitapanarux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S, Visetsiri E: Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1226-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
  • PURPOSE: This is a prospective, Phase III multicenter randomized trial to assess the effectiveness of concurrent intravenous mitomycin C, oral 5-fluorouracil (5-FU), and radiotherapy (RT) in locally advanced carcinoma of the cervix.
  • METHODS AND MATERIALS: Between January 1988 and November 1994, 926 patients with locally advanced carcinoma of the cervix, FIGO Stage IIB-IVA, were entered into this study.
  • The patients were randomized into four arms, as follows: Arm 1: conventional RT; Arm 2: conventional RT and adjuvant chemotherapy; Arm 3: conventional RT plus concurrent chemotherapy; Arm 4: conventional RT plus concurrent chemotherapy and adjuvant chemotherapy.
  • Concurrent chemotherapy consisting of intravenous mitomycin C at 10 mg/m(2) was given on Days 1 and 29, and oral 5-FU at 300 mg/day was administered on Days 1-14 and 29-42 during RT.
  • Adjuvant chemotherapy of 5-FU orally at 200 mg/day was given for three courses of 4 weeks, with a 2-week rest every 6 weeks.
  • RESULTS: The median follow-up time was 89 months.
  • Acute side effects were generally higher in concurrent arms, but most of the patients tolerated the treatment well.
  • At the time of analysis, there were no increases in late side effects, especially in gastrointestinal and genitourinary systems.
  • CONCLUSIONS: Concurrent chemotherapy, mitomycin C, and 5-FU together with conventional RT showed an improved DFS rate when compared with conventional RT alone in patients with locally advanced carcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Radioisotope Teletherapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Bone Marrow Diseases / chemically induced. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Gastrointestinal Diseases / chemically induced. Gastrointestinal Diseases / etiology. Humans. Injections, Intravenous. Life Tables. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Invasiveness. Prospective Studies. Radiation Injuries / etiology. Radiation-Sensitizing Agents / administration & dosage. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654431.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K: Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix. Br J Radiol; 2005 Sep;78(933):821-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix.
  • This study investigated treatment results and prognostic factors in radical radiotherapy for stage IIB-IVA cervical cancer.
  • This is a retrospective analysis of 71 patients with cancer of the uterine cervix treated radically with external beam radiotherapy and high-dose-rate intracavitary brachytherapy between June 1991 and May 2004.
  • In 47/71 (66%) of patients' chemotherapy was combined with radiotherapy.
  • The median follow-up time was 34.8 months.
  • The median age was 57 years (range 26-78 years) There were 21 patients (30%) in stage IIB, 3 (4%) stage IIIA, 40 (56%) stage IIIB, and 7 (10%) stage IVA.
  • The 5-year overall survival rate was 83.5%, 77.0%, and 42.9% for stage IIB, III, and IVA, respectively.
  • Federation Internationale de Gynocologie et d'Obstetrique (FIGO) classification stage and pelvic and para-aortic nodal status significantly affected survival in univariate analysis, but no treatment-related factor was found to be significant in multivariate analysis.
  • In this study para-aortic nodal status was the most important prognostic factor in the radical radiotherapy of cervical cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110104.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Karakousis CP: Surgical treatment of locally progressive stage IIIB carcinoma of the cervix: use of the inverted "T" incision. Eur J Obstet Gynecol Reprod Biol; 2004 Aug 10;115(2):216-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of locally progressive stage IIIB carcinoma of the cervix: use of the inverted "T" incision.
  • Stage III carcinoma of the cervix is treated usually, and often effectively, with the combination of radiation and chemotherapy.
  • The described surgical technique derives from soft tissue sarcoma pelvic surgery.
  • [MeSH-major] Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262359.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 7
  •  go-up   go-down


25. Sorbe B, Bohr L, Karlsson L, Bermark B: Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences. Int J Oncol; 2010 Feb;36(2):371-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.
  • In a series of 131 primary cervical carcinomas in FIGO stages I-IV suitable for combined external pelvic and intraluminal cervical-vaginal brachytherapy predictive and prognostic factors were analyzed with regard to locoregional tumor control, recurrences and survival data.
  • Patients with prior surgery or patients treated with external beam therapy alone were excluded from this series.
  • Concomitant chemotherapy was given to 47 patients (36%).
  • The external beam therapy was given with a four-field technique (50-60 Gy) and brachytherapy with high dose-rate (Ir-192) using a ring applicator set.
  • The dose (18-30 Gy) was specified according to the rules in ICRU 38 (a minimum dose to the surface of the target volume).
  • A CT-based 3-D dose-planning system (TMS) was used for the external beam therapy and for the brachytherapy planning (PLATO).
  • One hundred and eight tumors were in FIGO stages I-II and 23 tumors in stages III-IV.
  • A lower FIGO stage, chemoradiotherapy, squamous cell histology, diploid DNA-profile, a higher brachytherapy dose, more brachytherapy fractions and a higher total combined irradiation dose were favorable factors with regard to the risk of tumor recurrences.
  • The overall survival rate was 50% and the cancer-specific survival rate 65%.
  • Chemoradiotherapy therapy versus radiotherapy alone and squamous cell carcinomas versus adenocarcinomas were associated with improved survival rates.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043071.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):687-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • In our case, the biopsy of an exophytic lesion at the uterine cervix showed squamous cell carcinoma in a 50-year-old woman presenting with postcoital bleeding.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, para-aortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • The cervical carcinoma was staged as FIGO clinical stage IB1 and the lymphoma as Ann Arbor IIA.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolon) chemotherapy for the lymphoma and concomitant pelvic chemoradiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence, the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Int J Gynecol Cancer. 2015 Jul;25(6):1142 [26098094.001]
  • (PMID = 14675356.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Niibe Y, Hayakawa K, Tsunoda S, Kanai T, Imai M, Arai M, Arai T, Kawaguchi M, Jobo T, Hamada Y, Yago K, Unno N, Kitasato Gynecologic Radiation Oncology Group: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501). Jpn J Clin Oncol; 2007 Jan;37(1):70-2
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501).
  • In order to evaluate the safety and efficacy of chemoradiotherapy using nedaplatin for locally advanced uterine cervical carcinoma in Japanese patients, we have started a single-institute phase II trial.
  • Eligibility criteria include: (i) pathologically proven squamous cell carcinoma or adenocarcinoma, (ii) clinical FIGO stage Ib, IIa, or IIb with bulky tumor (> 40 mm) or pelvic lymph node swelling, or (iii) clinical FIGO stage IIIa, IIIb and IVa, (iv) no para-aortic lymph node swelling.
  • Nedaplatin (30 mg/m2) is intravenously infused on a weekly basis for five times.
  • The primary endpoint is 3-year overall survival, and the secondary endpoints are tumor response, 2-year overall survival, 3-year progression-free survival, acute adverse events, protocol treatment compliance, and late adverse events.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Organoplatinum Compounds / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Brachytherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Dose Fractionation. Female. Humans. Radiotherapy, High-Energy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204507.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


28. Lee KB, Lee JM, Park CY, Lee KB, Cho HY, Ha SY: What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1569-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study.
  • The objective of this study was to investigate the efficacy of treatment strategies in patients with adenocarcinoma (AC) of the cervix and compare it with those with squamous cell carcinoma (SCC) of the cervix.
  • Women with FIGO (1994) stage IB1 AC, especially pathologic tumor size of 2-4 cm, treated with class III hysterectomy, were compared with those with SCC treated with comparable strategy in a case-controlled study.
  • Primary radical surgery followed by adjuvant therapy, same as for SCC, would be acceptable for AC with pathologic tumor size of 2-4 cm.
  • Although it was difficult to determine whether AC recurred more systemically, more effective treatment strategies than those currently available for AC should be considered to reduce the systemic recurrence.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Case-Control Studies. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery. Endometrial Neoplasms / therapy. Female. Humans. Hysterectomy. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Retrospective Studies. Stromal Cells / pathology. Survival Rate


29. Macchia G, Ferrandina G, Deodato F, Ruggieri V, Massaccesi M, Salutari V, Valentini V, Cellini N, Scambia G, Morganti AG: Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). Gynecol Oncol; 2010 Aug 1;118(2):128-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1).
  • OBJECTIVE: To determine the recommended preoperative dose of large-field chemoradiation along with concomitant boost dose escalation on the tumor in locally advanced cervical carcinoma (LACC).
  • PATIENTS AND METHODS: A radiation dose of 40Gy over four weeks, 2Gy per fraction, was delivered to the tumor and the lymphatic drainage (planning target volume, PTV2), which encompassed a volume larger than standard (upper field border: L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil).
  • RESULTS: 32 patients (median age: 50 years; FIGO stage IB2: 4, IIA: 3, IIB: 21, III-IVA: 4) were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494419.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Bhosle SM, Huilgol NG, Mishra KP: Apoptotic index as predictive marker for radiosensitivity of cervical carcinoma: evaluation of membrane fluidity, biochemical parameters and apoptosis after the first dose of fractionated radiotherapy to patients. Cancer Detect Prev; 2005;29(4):369-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic index as predictive marker for radiosensitivity of cervical carcinoma: evaluation of membrane fluidity, biochemical parameters and apoptosis after the first dose of fractionated radiotherapy to patients.
  • BACKGROUND: This study was aimed to develop possible predictive response of cervical carcinoma in stage IIIA and B patients by evaluating the changes in physical parameter, such as, membrane fluidity, biochemical parameters, such as, intracellular calcium, antioxidant enzymes [superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx)] and apoptotic cell death in cervical cancer cells from patients after treating with the first fractionated dose of 2 Gy in radiation therapy protocol.
  • METHODS: Biopsies of cervical carcinoma patients were collected before and 24h after first fractionated radiation dose of 2 Gy.
  • Cell suspensions and tissue of cervix cancer biopsies were used to measure various physical and biochemical parameters.
  • RESULTS AND CONCLUSIONS: A negative correlation was found to exist between observed fluidity of membrane/SOD level with the degree of apoptosis in cervical cells.
  • These results suggest that changes in membrane fluidity, SOD and calcium level were involved in the mechanism of radiation induced cervical apoptosis as measured by TUNEL assay.
  • Moreover, apoptotic sensitivity of these cells after the first dose of radiation treatment showed a direct correlation with the radiation treatment outcome in patients after completion of radiotherapy protocol (70 Gy) in the clinic suggesting that apoptotic index may form a basis for prognosis in radiotherapy in stage III cervix cancer patients.
  • [MeSH-major] Apoptosis / radiation effects. Biomarkers, Tumor / radiation effects. Dose Fractionation. Membrane Fluidity / radiation effects. Radiation Tolerance / radiation effects. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Calcium / radiation effects. Catalase / radiation effects. Dose-Response Relationship, Radiation. Female. Glutathione Peroxidase / radiation effects. Humans. In Situ Nick-End Labeling. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Superoxide Dismutase / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125335.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; SY7Q814VUP / Calcium
  •  go-up   go-down


31. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer. Int J Gynecol Cancer; 2003 Jul-Aug;13(4):548-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B-cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • The biopsy of an exophytic lesion at the uterine cervix showed squamous cell carcinoma in a 50-year-old woman presenting with postcoital bleeding.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, paraaortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B-cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • The cervical carcinoma was staged as FIGO clinical stage IB1 and the lymphoma as Ann Arbor IIA.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) chemotherapy for the lymphoma and concomitant pelvic chemo-radiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence; the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12911737.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Nashiro T, Yagi C, Hirakawa M, Inamine M, Nagai Y, Sakumoto K, Tamaki W, Ogawa K, Toita T, Aoki Y: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. Int J Clin Oncol; 2008 Aug;13(4):335-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review.
  • BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT).
  • METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital.
  • Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA.
  • All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy.
  • Then two of the six patients underwent intracavitary vaginal brachy-therapy.
  • Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy.
  • One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months.
  • One patient with stage IVA developed a vesicovaginal fistula during CCRT.
  • Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system.
  • CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1982 Oct;14(2):154-63 [7129211.001]
  • [Cites] Gynecol Oncol. 2001 Jun;81(3):360-5 [11371123.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Nov;88(11):1145-50 [7295606.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):37-45 [10219792.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):892-7 [3967181.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):138-47 [15850914.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Baillieres Clin Obstet Gynaecol. 1987 Jun;1(2):319-29 [3319337.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Gynecol Oncol. 1991 Dec;43(3):233-6 [1752493.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):435-43 [7705681.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):758-70 [11241244.001]
  • [Cites] Gynecol Oncol. 1987 May;27(1):110-5 [3570044.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S29-42 [17161165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):1033-40 [9731908.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):110-7 [14764038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):891-905 [8751398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):901-6 [3141319.001]
  • (PMID = 18704634.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


33. Kreĭnina IuM, Titova VA, Shipilova AN, Povarova EV, Shevchenko LN: [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer]. Vopr Onkol; 2006;52(1):83-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer].
  • Clinical data on the management of squamous-cell cervical carcinoma stage II-III FIGO are presented.
  • At stage I, treatment included neoadjuvant polychemotherapy (NACT)--cisplatin 100 mg/m2, carboplatin 450 mg/m2 in conjunction with 5-FU 250 mg/m2 or paclitaxel 135 mg/m2.
  • According to protocol, two identical courses of NACT were given, at 21-28 day interval, followed by extended extirpation of the uterus (Wertheim).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Hysterectomy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome






Advertisement